Regulus Therapeutics Inc

+0.07 (+8.51%)
Earnings Announcements

Regulus Therapeutics Reports Q4 Loss Per Share of $0.03

Published: 03/09/2021 21:19 GMT
Regulus Therapeutics Inc (RGLS) - Regulus Therapeutics Reports Fourth Quarter and Year-end 2020 Financial Results and Recent Updates.
Q4 Loss per Share $0.03.
Q4 Earnings per Share Estimate $-0.12 -- Refinitiv Ibes Data (analyst estimates).
Qtrly Revenue Was $5.0 Million.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.08

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.08

More details on our Analysts Page.